Literature DB >> 32565183

Prevalence of Barrett's esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans.

Theresa H Nguyen1, Aaron P Thrift2, Massimo Rugge3, Hashem B El-Serag1.   

Abstract

BACKGROUND AND AIMS: Less than 10% of patients diagnosed with esophageal adenocarcinoma have a pre-existing Barrett's esophagus (BE) diagnosis, possibly because of suboptimal performance of guidelines. We examined the prevalence of BE in a previously unscreened primary care population and the potential yield of practice BE screening guidelines.
METHODS: This was a retrospective analysis of a prospective cross-sectional study of consecutively recruited unreferred patients from primary care clinics who underwent study upper endoscopy. We examined the performance of BE screening guidelines of the European Society of Gastrointestinal Endoscopy (ESGE), British Society of Gastroenterology (BSG), American Society for Gastrointestinal Endoscopy (ASGE), American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), and our own modification of guidelines.
RESULTS: We identified 44 BE cases and 469 control subjects (prevalence, 8.6%). Among 371 patients without GERD symptoms, 25 (6.7%) had BE. The AGA guidelines requiring ≥2 BE risk factors had sensitivity of 100% and specificity of only .2%, whereas ACG, ASGE, ESGE, and BSG guidelines (all requiring GERD first) had low sensitivities (38.6%-43.2%), specificities ranging from 67.4% to 76.5%, and area under the receiver operating curve (AUROC) of .50 to .60. Our 2-pronged approach depending on presence or absence of GERD symptoms but with other risk factors achieved sensitivity of 81.8%, specificity of 51.2%, and AUROC of .66.
CONCLUSIONS: Over half of BE cases were without frequent GERD symptoms, but virtually all had at least 1 known BE risk factor. Practice guidelines requiring GERD symptoms have low sensitivity, whereas those not requiring GERD have low specificity. We have proposed a screening guideline with better use of known risk factors.
Copyright © 2021 American Society for Gastrointestinal Endoscopy. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32565183      PMCID: PMC7749069          DOI: 10.1016/j.gie.2020.06.032

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  34 in total

1.  ASGE guideline on screening and surveillance of Barrett's esophagus.

Authors:  Bashar Qumseya; Shahnaz Sultan; Paul Bain; Laith Jamil; Brian Jacobson; Sharmila Anandasabapathy; Deepak Agrawal; James L Buxbaum; Douglas S Fishman; Suryakanth R Gurudu; Terry L Jue; Sapna Kripalani; Jeffrey K Lee; Mouen A Khashab; Mariam Naveed; Nirav C Thosani; Julie Yang; John DeWitt; Sachin Wani
Journal:  Gastrointest Endosc       Date:  2019-09       Impact factor: 9.427

2.  No Barrett's-No Cancer: A Proposed New Paradigm for Prevention of Esophageal Adenocarcinoma.

Authors:  David Y Graham; Mimi C Tan
Journal:  J Clin Gastroenterol       Date:  2020-02       Impact factor: 3.062

3.  Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia.

Authors:  Amitabh Chak; Ashley Faulx; Charis Eng; William Grady; Margaret Kinnard; Heather Ochs-Balcom; Gary Falk
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

Review 4.  Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?

Authors:  Aaron P Thrift
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

5.  Awareness of family health history as a risk factor for disease--United States, 2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-11-12       Impact factor: 17.586

6.  Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men.

Authors:  Jennifer R Kramer; Lori A Fischbach; Peter Richardson; Abeer Alsarraj; Stephanie Fitzgerald; Yasser Shaib; Neena S Abraham; Maria Velez; Rhonda Cole; Bhupinderjit Anand; Gordana Verstovsek; Massimo Rugge; Paola Parente; David Y Graham; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-12-04       Impact factor: 11.382

7.  Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.

Authors:  Lauren B Gerson; Peter W Groeneveld; George Triadafilopoulos
Journal:  Clin Gastroenterol Hepatol       Date:  2004-10       Impact factor: 11.382

8.  Gastroesophageal reflux among different racial groups in the United States.

Authors:  Hashem B El-Serag; Nancy J Petersen; Junaia Carter; David Y Graham; Peter Richardson; Robert M Genta; Linda Rabeneck
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

9.  Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival.

Authors:  Theresa Nguyen Wenker; Mimi C Tan; Yan Liu; Hashem B El-Serag; Aaron P Thrift
Journal:  Dig Dis Sci       Date:  2018-08-14       Impact factor: 3.199

10.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Authors:  Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker
Journal:  Gut       Date:  2013-10-28       Impact factor: 23.059

View more
  2 in total

1.  External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans.

Authors:  Theresa H Nguyen; Aaron P Thrift; Gyanprakash A Ketwaroo; Xianglin L Du; Luis Leon Novelo; Rollin George; Daniel G Rosen; Hashem B El-Serag
Journal:  Gastrointest Endosc       Date:  2022-01-06       Impact factor: 10.396

Review 2.  Artificial Intelligence in the Management of Barrett's Esophagus and Early Esophageal Adenocarcinoma.

Authors:  Franz Ludwig Dumoulin; Fabian Dario Rodriguez-Monaco; Alanna Ebigbo; Ingo Steinbrück
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.